Pentostatin injection
Products billed under this code include Nipent.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Nipent.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Nipent | Pfizer Inc | 00409-0801-01 | 1 | $2,612.893 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2,612.893 | −$85.094 | 10 MG | Pentostatin injection | v1, posted September 17, 2026 |
| 3Q26 | $2,697.987 | +$71.659 | 10 MG | Pentostatin injection | v1, posted September 15, 2026 |
| 2Q26 | $2,626.328 | +$89.232 | 10 MG | Pentostatin injection | v1, posted September 15, 2026 |
| 1Q26 | $2,537.096 | −$71.061 | 10 MG | Pentostatin injection | v1, posted September 15, 2026 |
| 4Q25 | $2,608.157 | +$64.263 | 10 MG | Pentostatin injection | v1, posted September 8, 2026 |
| 3Q25 | $2,543.894 | −$129.537 | 10 MG | Pentostatin injection | v1, posted March 10, 2026 |
| 2Q25 | $2,673.431 | −$59.10 | 10 MG | Pentostatin injection | v1, posted March 10, 2026 |
| 1Q25 | $2,732.531 | +$190.757 | 10 MG | Pentostatin injection | v1, posted December 19, 2025 |
| 4Q24 | $2,541.774 | +$4.707 | 10 MG | Pentostatin injection | v1, posted June 11, 2025 |
| 3Q24 | $2,537.067 | +$201.344 | 10 MG | Pentostatin injection | v1, posted June 11, 2025 |
| 2Q24 | $2,335.723 | +$62.57 | 10 MG | Pentostatin injection | v1, posted March 11, 2025 |
| 1Q24 | $2,273.153 | −$63.826 | 10 MG | Pentostatin injection | v1, posted December 19, 2024 |
| 4Q23 | $2,336.979 | −$50.746 | 10 MG | Pentostatin injection | v1, posted October 10, 2024 |
| 3Q23 | $2,387.725 | −$197.689 | 10 MG | Pentostatin injection | v1, posted June 5, 2024 |
| 2Q23 | $2,585.414 | +$265.298 | 10 MG | Pentostatin injection | v1, posted February 23, 2024 |
| 1Q23 | $2,320.116 | +$113.674 | 10 MG | Pentostatin injection | v1, posted December 6, 2023 |
| 4Q22 | $2,206.442 | +$130.363 | 10 MG | Pentostatin injection | v1, posted June 22, 2023 |
| 3Q22 | $2,076.079 | +$10.762 | 10 MG | Pentostatin injection | v1, posted June 9, 2023 |
| 2Q22 | $2,065.317 | +$130.863 | 10 MG | Pentostatin injection | v1, posted December 14, 2022 |
| 1Q22 | $1,934.454 | +$53.788 | 10 MG | Pentostatin injection | v1, posted June 8, 2022 |
| 4Q21 | $1,880.666 | −$90.336 | 10 MG | Pentostatin injection | v1, posted June 2, 2022 |
| 3Q21 | $1,971.002 | −$31.908 | 10 MG | Pentostatin injection | v1, posted June 2, 2022 |
| 2Q21 | $2,002.91 | +$1.015 | 10 MG | Pentostatin injection | v1, posted March 1, 2022 |
| 1Q21 | $2,001.895 | – | 10 MG | Pentostatin injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.